SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

July 30, 2028

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

JMT101

JMT101 Q2W or Q3W, intravenous injection

DRUG

SYS6002

SYS6002 Q2W or Q3W, intravenous injection

DRUG

SG001

SG001 Q2W or Q3W, intravenous injection

All Listed Sponsors

lead

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY